Analysis

Pharma Technology Focus – Issue 57

Pharma Technology Focus – Issue 57

Turning to turmeric: exciting drug candidate or another dead end?

Turning to turmeric: exciting drug candidate or another dead end?

BlueRock Therapeutics: Ontario’s home-grown stem cell contender

BlueRock Therapeutics: Ontario’s home-grown stem cell contender

Takeda turns its focus overseas

Takeda turns its focus overseas

Learning from tragedy: safety and dosing in first-in-human trials

Learning from tragedy: safety and dosing in first-in-human trials

Using shark antibodies to treat Alzheimer’s disease

Using shark antibodies to treat Alzheimer’s disease

How an Alzheimer’s drug turned tooth regenerator could unlock regenerative medicine

How an Alzheimer’s drug turned tooth regenerator could unlock regenerative medicine

Moving mountains: balancing safety and speed in drug development

Moving mountains: balancing safety and speed in drug development

Medicines Discovery Catapult: improving collaborative drug discovery in the UK

Medicines Discovery Catapult: improving collaborative drug discovery in the UK

Therapeutic orphans: child-friendly drugs and the quest for adherence

Therapeutic orphans: child-friendly drugs and the quest for adherence

A peptide to prevent pre-diabetes

A peptide to prevent pre-diabetes

Pharma Technology Focus – Issue 56

Pharma Technology Focus – Issue 56

The Hive: new incubator makes a beeline for non-traditional pharma companies

The Hive: new incubator makes a beeline for non-traditional pharma companies

BenevolentAI: using artificial intelligence to speed up drug discovery

BenevolentAI: using artificial intelligence to speed up drug discovery

Pharma Technology Focus – Issue 55

Pharma Technology Focus – Issue 55

Pharma payments to doctors: seeking transparency

Pharma payments to doctors: seeking transparency

How does the NHS weigh the costs of HIV preventing drugs?

How does the NHS weigh the costs of HIV preventing drugs?

India's drug price overhaul: a question of balance

India's drug price overhaul: a question of balance

Pay-for-delay: how far will companies go to protect market exclusivity?

Pay-for-delay: how far will companies go to protect market exclusivity?

Pharma Technology Focus – Issue 54

Pharma Technology Focus – Issue 54

Debating the value of targeted lung cancer treatments

Debating the value of targeted lung cancer treatments
cachename:Featurescachekey:rd-137342983_-779801984_rd-1665407042_727740091_rd-488908060_1460672566_ap1460672566_727740091_-88152200